205 2 2 doi:0.3969/j.issn. 672-5972.205.0.004 swgk204-09-060 ORTHOPAEDIC BIOMECHANICS MATERIALS AND CLINICAL STUDY.5. / *,2 3 [ ] /3% 5% / - HPLC-ELSD PMMA / PMMA 4 2 5% / 3% / PMMA/ / PMMA [ ] [ ] R308.08 [ ] A Elution characteristics of gentamycin from Calcium Sulfate/Getamycin delivery system [Abstract] Objective To discuss the elution characteristics of gentamycin from bone-implanted local antibiotic delivery system, Calcium Sulfate/Gentamycin. Methods To elute the gentamycin from the antibiotic delivery system, Calcium Sulfate/Gentamycin(CaS/GM)and PMMA/ Gentamycin PMMA/GM delivery system, the concentration of gentamycin in the eluted fluid in different time was determined by HPLC. The elution characteristics of different delivery system in vitro werecompared. Results ThereleasingtimeofGentamycinfromeCaS/GM andpmma/gm lastedfor4weeks and 2 weeks individually, the concentration of gentamycin in the eluted fluid during early periods was higher than that during later periods. In the same time gentamycin was released more from the 5% CaS/GM than from 3% CaS/GM. Comparing with PMMA/GM delivery system, gentamycin was also released more from CaS/GM. Conclusion CaS/GM antibiotic delivery system can be biodegraded, from CaS/GM than that from PMMA/GM individually, system on antibiotic release and biodegradation. and the releasing time is longer and the releasing amount of gentamycin is higher CaS/GM antibiotic delivery system is superior to PMMA/GM [Key words] Localantibiotic deliverysystem; Calcium sulfate; Gentamycin; Biodegradation; Highperformanceliquid chromatography (HPLC) (PMMA) [,2] * : 06MA26 : 00853 2 25709 3 25709 PMMA [3,4]... /
.6. ORTHOPAEDIC BIOMECHANICS MATERIALS AND CLINICAL STUDY 205 2 2 3% 5% PBS (Sigma ) ( Sigma ) (PMMA )..2 : 37 ( Agilent00 ) ( Alltech ELSD2000).2.2. / (CaS/GM) (PMMA/GM) [4] : / CaS/GM (45±.26) mg 40gPMMA 2g 20mL 5~0 03mg 60.2.2 : 3% 5% CaS/GM PMMA/GM 0 5 6mLPBS 37 24 0 4 2 28 35 42 2mL -20 PBF.2.3 C8 0.2mol/L - (92 : 8) ml/min : 0 : 2.8L/min : 20uL : () : mg/ml 500 250 00 50 0 5ug/mL 5000r/min 5 5 ( 2 3 ) (2) 20uL (3) 20uL 2 2. Ca, C, C2, C2a C2b [5] C Ca, C2, C2b, C2a, C 2.2 2.3 [6] Ca ( 2) 0.999 Y=.695+0.675X (Y X ) 2 2.4 3 4 3% 5%CaS/GM
205 2 2 ORTHOPAEDIC BIOMECHANICS MATERIALS AND CLINICAL STUDY.7. 3 3%CaS/GM 4 5%CaS/GM 5 Cas/GM PMMA/GM (ug/ml) 3%Cas/GM 5%Cas/GM 5%PMMA/GM d 2d 3d 4d 5d 6d 7d 0d 854.79 376.9 270.47 88.33 43.77 93.96 80.5 2.47 384.3 775.2 5.74 383.46 287.72 88.25 74.53 6. 349.37 40.69 03. 46.55 35.03.33 0.66 6.57 4d 9.94 45.2 6.2 2d 28d.48 5.4 6.67 7.72 5 Cas/GM PMMA/GM 2.5 CaS/GM PMMA/GM 3 Mclaren [7] 00mL 40 Ca, C, C2, C2a C2b [5] HPLC C - (HPLC- ELSD) [5,6] : : : [8-0] 5% CaS/ GM 3% 24 50% [] PMMA/GM CaS/GM 4 MIC (<2ug/mL) CaS/GM
.8. ORTHOPAEDIC BIOMECHANICS MATERIALS AND CLINICAL STUDY 205 2 2 [] Buchholz HW, Elson RA, Engelbrecht E, et al. Management of deep infection of total hip replacement. J Bone Joint Surg.98, 63 (B): 342-353. [2] Lin SS, Ueng, SWN, et al. Development of a biodegradable antibiotic delivery system. Clin Orthop, 999, 362: 240-250. [3]. /. 2008 2 36. [4]. / / /. 2009 6():-4. [5].. : 4 IL-7 IL-7A CIA IL-7A CIA+ TNF-a IL-7 IL-6 ( <0.05) IL-7 TNF-a IL-7 IL-6 IL-7A CIA IL-7A IL-7 /RANKL IL-7 CIA Th7 RA RA []. Th7 [J]. 2009 : 732-735. [2] Carney EF. Therapy: TNF inhibition suppresses angiogenic mechanisms implicated in RA [J]. Nat Rev Rheumatol, 202, 8 :307. [3] Buckland, J. Rheumatoid arthritis: Control of T(H)7 cell activity in RA by a combination of vitamin D receptor signaling and TNFblockade [J]. Nat Rev Rheumatol, 202, 8(3): 24. [4] Nagahara M,Waguri-Nagaya Y,Yamagami T,et al.nf-alpha-induced aquaporin 9 in synoviocytes from patients with OA and RA [J]. 2000 82. [6]. - C. 2002 22(6): 46-464. [7] McLaren AC, McLaren SG, Nelson CL, et al. The effect of sampling method on the elution of tobramycin from calcium sulfate. Clin Orthop, 2002, 403: 54-57. [8] McLaren AC. Alternative materials to acrylic bone cement for deliveryof depot antibiotics in orthopaedic infections. Clin Orthop, 2004, 427: 0-06. [9] Nelson CL. The current status of materials Used for Depot Delivery of Drugs. Clin Orthop, 2003,427: 72-78. [0] Wichelhaus TA, Dingeldein E, Rauschmann M, et al. Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. J Antimicrob Chemother, 200, 48:7-9. [] Soriano I, Evora C. Formulation of calcium phosphates /poly(d,llactide) blends containing gentamicin for bone implantation. Journal of Con trolled Release,2000(68): 2-34. [ ] (969-) : ( :204-09-09) Rheumatology(Oxford), 200, 49:898-906. [5] Karin Palmblad, Helena Erlandsson-Harris, Kevin J,et al. Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: A Therapeutic Study Using a Macrophage-Deactivating Compound [J]. Am J Pathol, 200, 58(2):49-500. [6] Akerlund K, Erlandsson-Harris H, Tracey KJ, Wang H, Fehniger T, Klareskog L, Andersson J, Andersson U: Anti-inflammatory effects of a new tumor necrosis factor-alpha (TNF-a) inhibitor (CNI-493)incollagen-induced arthritis(cia)in rats [J]. Clin Exp Immunol,999, 5: 32-4. [7].. [8] Joyce E. Matrix metalloproteinases, angiogenesis, and cancer [J]. ClinCancerRes, 2003, 9: 55. [9]. -6 [J]. 203 7(0): 699-702. [0] Hashimoto M, Mimori T. Role of Th7 cells and innate immunity for the induction of autoimmune arthritis[j]. Nihon Rinsho Meneki Gakkai Kaishi, 202, 35: 463-469. [] Sato K, Suematsu A, Okamoto K, et al. Th7 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction [J]. J ExpMed, 2006, 203(2): 2673-2682. [2] Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-7 antibody after the onset of collagen-induced arthritis reduces joint inflammation, Cartilage destruction, and bone erosion. Arthritis Rheum 2004,50:650-659. [ ] (979-) : *[ ] : ( :204-0-3)
«长*刼.一64208642oooooootx8765432CIA 小鼠体重变化 5) 3-A 组 B 组 -C 组 -D 组 ( 一<-A 组 -B 组 -C 组 - 线性 < 八组 } 6 8 0 2 4 6 8 0 2 4 CIA 小鼠鳆腔注射中和抗体后的时间 t/d> 时间 t/d o丨冬丨 2 (: 丨 A 小鼠 4 内天小鼠体重变化图 3 CIA 小鼠 4 天的平均关节炎指数 MAI ) 硫酸钙 / 庆大霉素抗生素释放系统的抗生素释放规律 * 于学忠 2 任思庆 陈 # 李宁 ' 梁向党 唐佩福 张伯助 (Is/sn)«崧铝IX( 黑旬图见文中第 7 页 ) - 3%Cas/GM 5%Cas/GM 5%PMMA/GM TD T3 T3 T3 T3 HD T3 T3T3TD CNJCO 寸 LOCO 卜 O -H OO t CM CS^ 时间 (d) 图 5 Cas/GM PMMA/GM 各时间的抗生素浓度图 经改良设计的骨髓穿刺输液针输液复苏失血性休克犬效果的实验研究 夏俊杰侯春林 ' 宗海洋 ( 黑白阁见文中第 40,4 页 ) j/ / HI >y/>i >f% 5 ML 攀 ;ji jk.^ g '^ : 7 / i 8, 眷 图 2 骨髓穿刺输液针橾作步骤 : 切开皮肤 ;2 钻孔 ;3 钻入骨髓穿刺 ;4 置入骨髓穿刺针完成 ;5 拔出内套针 ;6 右股骨动脉放血建立休克模型 ;7 针尾部接? 通, 注入肝索化牛现盐观察通畅度 ;8 穿刺针接输液器幵始输液复苏休克